Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?

@article{Petrelli2009CurrentDO,
  title={Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?},
  author={Fausto Petrelli and Mary Cabiddu and Mara Ghilardi and Sandro Barni},
  journal={Expert opinion on investigational drugs},
  year={2009},
  volume={18 10},
  pages={1467-77}
}
Approximately 10 - 15% of breast carcinomas (BCs) are known to be 'triple-negative (TN) receptor' (i.e., not expressing ER or PR and not exhibiting overexpression and/or gene amplification of HER2-neu). Triple-negative BCs comprise approximately 85% of all basal-type tumours. Classically, basal-like BCs have been characterised by low expression of ER, PR, and HER2 neu and high expression of CK5, CK14, caveolin-1, CAIX, p63, and EGFR (HER1), which reflects the mammary gland basal/myoepithelial… CONTINUE READING